Skip to main content
Signal8
Launch Terminal

RECURSION PHARMACEUTICALS, INC. (RXRX)

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc.

NASDAQ:RXRXHealthcare
-4.95%$4.03
AH$4.02-0.25%vs close
Mkt Cap$2.41B
Float431.97M
O/S597.81M
Vol
$ Vol
RVOL
Inst Own60.1%
SI37.5%
Earnings
Dilution
Recursion Pharmaceuticals, Inc. logoNASDAQ:RXRX$4.03-4.95%
Phase Distribution
10 lead-sponsored trials·6 active·1 completed
Phase 12
Phase 1/24
Phase 23
Phase 2/31
Status Overview
Recruiting6
Completed1
Stopped3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2/3
    Terminated

    Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

    REC-2282, Placebo

    Neurofibromatosis Type 2

    Enrollment
    25
    Start
    Jun 2022
    Primary Completion
    Aug 2025
    Completion
    Aug 2025
    NCT05130866
  • Phase 2
    Completed

    The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

    REC-994, Placebo

    Cerebral Cavernous Malformation

    Enrollment
    62
    Start
    Mar 2022
    Primary Completion
    Jun 2025
    Completion
    Jun 2025
    NCT05085561
  • Phase 2
    Terminated

    A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

    REC-4881

    AXIN1 Gene Mutation, APC Gene Mutation +1

    Enrollment
    18
    Start
    Jan 2024
    Primary Completion
    Feb 2025
    Completion
    Feb 2025
    NCT06005974
  • Phase 2
    Terminated

    The Clostridioides Difficile Trial of REC-3964

    REC-3964

    Recurrent Clostridioides Difficile Infection

    Enrollment
    3
    Start
    Oct 2024
    Primary Completion
    May 2025
    Completion
    May 2025
    NCT06536465
  • Phase 1/2
    Recruiting

    Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

    REC-4881, Placebo

    Familial Adenomatous Polyposis

    Enrollment
    67
    Start
    Jul 2023
    Primary Completion
    Jun 2027est.
    Completion
    Sep 2027est.
    NCT05552755
  • Phase 1/2
    Recruiting

    Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

    GTAEXS617, SoC

    Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma +4

    Enrollment
    230
    Start
    Jul 2023
    Primary Completion
    Jan 2028est.
    Completion
    May 2028est.
    NCT05985655
  • Phase 1/2
    Recruiting

    A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

    REC-1245

    Unresectable, Locally Advanced +2

    Enrollment
    170
    Start
    Nov 2024
    Primary Completion
    Oct 2028est.
    Completion
    Oct 2028est.
    NCT06678659
  • Phase 1/2
    Recruiting

    REC-7735 in Participants With Solid Tumors

    REC-7735

    Solid Tumors

    Enrollment
    90
    Start
    Sep 2026est.
    Primary Completion
    Jan 2031est.
    Completion
    Jan 2031est.
    NCT07819136
  • Phase 1
    Recruiting

    Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

    EXS73565

    Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) +5

    Enrollment
    85
    Start
    Mar 2025
    Primary Completion
    Jun 2028est.
    Completion
    Dec 2028est.
    NCT06980116
  • Phase 1
    Recruiting

    Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

    EXS74539

    Solid Tumor, Small Cell Lung Cancer (SCLC) +10

    Enrollment
    40
    Start
    Apr 2026
    Primary Completion
    Mar 2029est.
    Completion
    Mar 2029est.
    NCT07517198
Search ClinicalTrials.gov for “Recursion Pharmaceuticals”